Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Baxter/Cerus: Baxter Capital Corporation aims to recall a $50 mil. loan to Cerus through legal proceedings, alleging that the firm's recent termination of Phase III clinical trials for the Intercept pathogen inactivation system for red blood cells constitutes default under the terms of the credit facility (1"The Gray Sheet" Sept. 8, 2003, p. 14). Cerus disagrees, asserting that interest and principle on the loan, which commenced in January, are not due until 2008. Cerus also notes it is cutting its current workforce by about 40 people, or roughly 25%, and R&D expenses for 2003 by approximately $5-$10 mil. The move will produce $20-$25 mil. in projected 2004 savings. The firms' relationship in developing Intercept for platelets is unaffected by the financing issue, Cerus says...

You may also be interested in...



Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex

Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells

Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex

Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells

Financings In Brief

WorldHeart relisting: Stock (WHTOF) resumes trading on Nasdaq at $9.50 following seven-to-one consolidation approved by shareholders Nov. 25, 16 months after being delisted. On Sept. 23, the company issued $63.5 mil. in common stock and converted $58 mil. of preferred shares into roughly 5 mil. common shares. Shareholders also agreed to convert the remaining $20 mil. in preferred shares and $3.5 mil. in accrued dividends. Following the restructuring and consolidation, the Ottawa firm has no preferred shares outstanding, about 15 mil. common shares and no debt. WorldHeart recently announced a new strategy for the U.S. marketing of its Novacor left-ventricular assist device, taking advantage of Medicare reimbursement for investigational LVADs (1"The Gray Sheet" Nov. 10, 2003, p. 39)...

Related Content

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel